These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 2418245)
1. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245 [TBL] [Abstract][Full Text] [Related]
2. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381 [TBL] [Abstract][Full Text] [Related]
3. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein]. Shinoda I Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555 [TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Killian CS; Yang N; Emrich LJ; Vargas FP; Kuriyama M; Wang MC; Slack NH; Papsidero LD; Murphy GP; Chu TM Cancer Res; 1985 Feb; 45(2):886-91. PubMed ID: 2578313 [TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer]. Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571 [TBL] [Abstract][Full Text] [Related]
8. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Morote J; Lorente JA; Encabo G Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009 [TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer. Saito T; Hara N; Kitamura Y; Komatsubara S Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541 [TBL] [Abstract][Full Text] [Related]
10. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up. Bauer HW Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908 [TBL] [Abstract][Full Text] [Related]
11. [Tumor markers of prostate cancer--evaluation of serum PAP and PA]. Miki M Gan No Rinsho; 1985 May; 31(6 Suppl):664-9. PubMed ID: 2411965 [TBL] [Abstract][Full Text] [Related]
12. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Tarle M Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362 [TBL] [Abstract][Full Text] [Related]
13. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. Wang TY; Kawaguchi TP Ann Clin Lab Sci; 1986; 16(6):461-6. PubMed ID: 3800301 [TBL] [Abstract][Full Text] [Related]
14. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. Moul JW; Connelly RR; Perahia B; McLeod DG J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187 [TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of a prostate-specific antigen as a serum marker of prostatic cancer]. Park YC; Kiwamoto H; Nishioka T; Tsujihashi H; Mitsubayashi S; Matsuura T; Akiyama T; Kurita T; Miyamoto T Hinyokika Kiyo; 1987 Jun; 33(6):883-8. PubMed ID: 2445188 [TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein]. Yoshiki T; Okada K; Oishi K; Yoshida O Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559 [TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer. Mortarelli EA Ann Clin Lab Sci; 1992; 22(4):201-6. PubMed ID: 1380223 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of advanced prostatic carcinoma. Lukkarinen O; Lehikoinen K Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878 [TBL] [Abstract][Full Text] [Related]
19. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate]. Morote Robles J; de Torres Mateos JA Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148 [TBL] [Abstract][Full Text] [Related]
20. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions. Tarle M Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]